arrow
J

Jaap C. Reijneveld

Amsterdam University Medical Center
H指数:71
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health-Related Quality of Life in Molecular Glioma Subtypes: A Pooled Analysis from 16 Randomized Trials

分子胶质瘤亚型的健康相关生活质量:一项来自16项随机试验的合并分析

2025-11-010
OAAI
Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer

在晚期癌症临床试验中报告与健康相关的生活质量数据时,应答者标准的重要性:常识肿瘤学与欧洲癌症研究与治疗组织的建议

2025-09-010
PRE
Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure

胶质母细胞瘤的随机多中心III期临床试验EORTC-1709-BTG/CCTG CE.8 (MIRAGE)中的质量保证:放射治疗勾画基准案例程序的结果

2025-08-100
PRE
Establishing the content validity of patient-reported outcome measures used in neuro-oncology based on the WHO ICF framework: Part of the RANO-PRO initiative

基于WHO ICF框架建立神经肿瘤学中使用的患者报告结局指标的内容效度:RANO-PRO计划的一部分

2025-06-010
PRE
Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study

基线EORTC QLQ-C30评分对总体生存的预测价值:一项涵盖17种癌症类型的46项临床试验的验证研究

2025-04-010
PRE
RADIOTHERAPY VERSUS TMZ FOR HIGH-RISK LOW-GRADE GLIOMA. FINAL RESULTS AFTER MEDIAN FOLLOW-UP OF 13 YEARS OF PHASE III EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) STUDY
2024-11-110
PRE
Instrumental activities of daily living in neuro-oncology: International validation of the EORTC IADL-BN32 questionnaire
2024-11-011
OAAI
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial

Marizomib用于新诊断的胶质母细胞瘤患者: 一项随机3期试验

2024-03-192
OAAI
LONG-TERM SURVIVAL WITH IDH WILDTYPE GLIOBLASTOMA: FIRST RESULTS FROM THE ETERNITY BRAIN TUMOR FUNDERS' COLLABORATIVE CONSORTIUM (EORTC 1419)
2023-09-080
OA
Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first- recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091)
2023-09-015
OA